Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
XORTX Therapeutics Inc ( (TSE:XRTX) ) has shared an announcement.
On October 29, 2025, XORTX Therapeutics Inc. announced the closing of a registered direct offering, raising gross proceeds of US$1.1 million. The offering involved the sale of 1,750,000 common shares and pre-funded warrants, with the proceeds intended for working capital and general corporate purposes. The transaction, facilitated by D. Boral Capital LLC as the sole placement agent, is expected to bolster XORTX’s operational capabilities and support its ongoing clinical programs.
The most recent analyst rating on (TSE:XRTX) stock is a Buy with a C$14.00 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.
Spark’s Take on TSE:XRTX Stock
According to Spark, TipRanks’ AI Analyst, TSE:XRTX is a Underperform.
XORTX Therapeutics Inc faces significant challenges with no revenue and consistent losses, leading to a low financial performance score. Technical analysis indicates a neutral to bearish outlook, which, along with poor valuation metrics, weighs down the overall stock score. However, potential advancements in FDA discussions for gout treatment provide a glimmer of hope for future revenue generation, but current financial and compliance risks remain substantial.
To see Spark’s full report on TSE:XRTX stock, click here.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies for treating gout and progressive kidney disease. The company is advancing products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. XORTX is committed to improving the quality of life and health of individuals with gout and other significant diseases.
Average Trading Volume: 11,926
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$5.09M
For a thorough assessment of XRTX stock, go to TipRanks’ Stock Analysis page.